Medivir Q4’20: Focus Turns to MIV-818
Research Note
2021-03-01
07:20
Redeye reiterates its base case for Medivir following the Q4’20 report. Upcoming MIV-818 updates will determine share sentiment, and we remain cautiously optimistic.
NE
Niklas Elmhammer
Disclosures and disclaimers